DTIL

Precision BioSciences, Inc.

14.63 USD
-3.93 (-21.17%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Precision BioSciences, Inc. stock is up 28.33% since 30 days ago. The next earnings date is Mar 11, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 20% of the previous 4 February’s closed higher than January. 100% of analysts rate it a buy.

About Precision BioSciences, Inc.

Precision BioSciences offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which a specific type of immune cell, called a T cell, is genetically engineered to recognize and kill cancer cells. PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL.